Credit rating
Company information
About VELIN-PHARMA A/S
VELIN-PHARMA A/S (CVR number: 33026013) is a company from FREDENSBORG. The company recorded a gross profit of 161.4 kDKK in 2022. The operating profit was 161.4 kDKK, while net earnings were 5547.3 kDKK. The profitability of the company measured by Return on Assets (ROA) was 20.6 %, which can be considered excellent and Return on Equity (ROE) was 16.3 %, which can be considered excellent. The equity ratio, a key indicator for solidity, stood at 95.7 %, a level that can be considered to be very good, which means that the majority of assets are financed by equity. VELIN-PHARMA A/S's liquidity measured by quick ratio was 23.1 which is at a very high level. Thus, the company demonstrates exceptional financial stability, possessing a significant surplus of liquid assets over its short-term liabilities.
Financial information
See financialsGross profit (kDKK)
EBIT (kDKK)
Profitability
Solidity
Key figures (kDKK)
See financials2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Volume | |||||
Net sales | |||||
Gross profit | 139.06 | 278.65 | 150.16 | 439.91 | 161.40 |
EBIT | 139.06 | 278.65 | 150.16 | 439.91 | 161.40 |
Net earnings | - 997.97 | 3 483.81 | 5 954.07 | 3 117.18 | 5 547.26 |
Shareholders equity total | 18 686.41 | 22 170.22 | 28 124.29 | 31 241.47 | 36 788.73 |
Balance sheet total (assets) | 19 115.99 | 22 714.90 | 29 882.11 | 32 076.04 | 38 448.47 |
Net debt | -13 716.03 | -16 868.11 | -23 786.70 | -26 989.28 | -34 349.84 |
Profitability | |||||
EBIT-% | |||||
ROA | 6.7 % | 20.5 % | 29.0 % | 12.9 % | 20.6 % |
ROE | -5.2 % | 17.1 % | 23.7 % | 10.5 % | 16.3 % |
ROI | 6.8 % | 20.8 % | 30.3 % | 13.5 % | 21.4 % |
Economic value added (EVA) | -49.83 | 105.17 | -44.30 | 218.95 | 5.92 |
Solvency | |||||
Equity ratio | 97.8 % | 97.6 % | 94.1 % | 97.4 % | 95.7 % |
Gearing | 0.7 % | 0.6 % | |||
Relative net indebtedness % | |||||
Liquidity | |||||
Quick ratio | 38.8 | 37.7 | 15.8 | 35.8 | 23.1 |
Current ratio | 39.9 | 38.1 | 15.9 | 36.2 | 23.2 |
Cash and cash equivalents | 13 844.57 | 17 001.96 | 23 786.70 | 26 989.28 | 34 349.84 |
Capital use efficiency | |||||
Trade debtors turnover (days) | |||||
Net working capital % | |||||
Credit risk | |||||
Credit rating | BBB | A | A | A | BB |
Variable visualization
Roles
Companies in the same industry
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.